EU pharmacies resist wholesaling changes; Teva cutting 200 at Irvine plant;

> EU pharmacy leaders oppose the Medicines and Healthcare Products Regulatory Agency's plan to review drug wholesaling practices with an eye toward eliminating complexity. Article

> Generics-maker Teva Pharmaceuticals is cutting 200 production and support-staff jobs at its Irvine, CA, plant, most by the first week in February. Story

> Shire has completed construction of a manufacturing plant in the Boston suburb of Lexington, in which it plans to make Replagal and Vpriv. Article

> AstraZeneca is continuing its serialization push: ten manufacturing sites and 30 production lines now produce drugs having item-level serial numbers on their packaging. Article

> Grand Bahama eyes the drug and chemical industries in its ambition to become a transportation and logistics hub for maritime and air cargo operations. Item

> The UK's Fairfield Group has launched a scanner that reads 2D data matrix barcodes in addition to traditional barcodes and Pharmacodes. Fairfield release

> Catalent Pharma Solutions is enhancing its sourcing program for the supply of comparator drugs used in clinical trials. Catalent release

> Actavis Group has expanded its geothermally powered, zero-carbon-footprint tablet manufacturing and packaging operation in Iceland. News

> Both the FDA and ASHP maintain drug-shortage lists; the FDA's includes nearly 60 medically necessary products while the more comprehensive ASHP list includes more than 140 drugs. Report

Suggested Articles

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.

It took four tries over four years, but Perrigo has finally gotten FDA approval of its generic of Teva’s tricky-to-make ProAir HFA asthma inhaler.